Latest News

  • Alkermes to Host Conference Call to Discuss First Quarter 2015 Financial Results Read More
  • Alkermes to Present Preclinical Data on Novel Selective Effector Cell Activator (SECA™) Immuno-Oncology Candidate at Upcoming American Association for Cancer Research Annual Meeting Read More
  • Alkermes Announces Positive Topline Results from Complete Six-Month Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia Read More

Investors

Learn More

Working at Alkermes

Join Our Team